Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finerenone - Bayer HealthCare Pharmaceuticals

Next Previous
X
Search
Drug Profile

Finerenone - Bayer HealthCare Pharmaceuticals

Alternative Names: Kerendia; BAY-94-8862; KERENDIA; Kerendia

Latest Information Update: 24 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Amides; Antihyperglycaemics; Heart failure therapies; Naphthyridines; Nitriles; Small molecules; Urologics
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies
  • Phase III Chronic heart failure; Heart failure; Renal failure; Type 1 diabetes mellitus

Most Recent Events

  • 14 Jun 2024 Bayer completes a phase-III clinical trial in Heart failure in US, Argentina, Austria, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Netherlands, New Zealand, Poland, Portugal, Russia, Slovakia, Spain, Turkey, Ukraine, UK, Australia, Finland, Hong Kong, India, Latvia, Lithuania, Mexico, Malaysia, Romania, Taiwan (PO) (NCT04435626)
  • 26 Feb 2024 Phase-III clinical trials in Renal failure (Adjunctive treatment) in China (PO) (NCT05901831)
  • 26 Feb 2024 Phase-III clinical trials in Type 1 diabetes mellitus (Adjunctive treatment) in United Kingdom, China (PO) (NCT05901831)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top